PMC

(A) Establishment periods of all successful PDX models (B) F1-F2 and F1-F3 intervals according to status of neoadjuvant chemotherapy.

(A) Proportion of breast cancer subtypes. (B) Successful engraftment of PDX models were derived from TNBC patient with or without neoadjuvant chemotherapy.

(A) H&E staining and immunohistochemistry of PDX models and primary tumor of patients. (B) Ki67 expression of PDX models. (C) Positive control of ER, PR and HER2 in immunohistochemistry.

(A) PDX models were derived from patients who had BRCA1 mutation (n = 2) or wild-type BRCA1 (n = 1). Each model comprise nine mice, which were divided into three groups (1 group = 3 mouse, two single treatment groups and one vehicle group). (B-E) When implanted tumor reached an average size of 200–250 mm³ (Volume = 0.5×Length×Width^2), the chemosensitivity test was performed. Olaparib (50mg/kg, once a daily) and carboplatin (25mg/kg, once a weekly) were administered by an intra-peritoneal (i.p.) route. Phosphate buffered saline was used to as a vehicle.